Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CM082 + paclitaxel
- Development stage
- Phase 1
- Lead developer
- Betta Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral (CM082), Intravenous (paclitaxel)[1]
01
Overview
CM082 (vorolanib) combined with paclitaxel is an investigational combination therapy being studied primarily for advanced gastric cancer. CM082 (also known as vorolanib or X-82) is a small molecule multi-target tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and other kinases involved in tumor angiogenesis and proliferation. Paclitaxel is a well-established chemotherapeutic agent that stabilizes microtubules, thereby inhibiting cell division and inducing apoptosis in rapidly dividing cancer cells. The combination aims to leverage the antiangiogenic effects of CM082 with the cytotoxic activity of paclitaxel to improve outcomes in patients with advanced cancers, particularly those who have failed prior therapies[1][2][3].
- Other names
- vorolanib + paclitaxel
02
Targets
ABCG2 (Breast cancer resistance protein)CSF1R (Macrophage colony-stimulating factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on CM082 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CM082 + paclitaxel.